THE TEAM

• “PET Imaging of PD-L1 Occupancy for Preclinical Assessment of the Efficacy of Combined Anti-PD-L1 Immunotherapy and Targeted Therapy.”, Chevaleyre C, Zimmermann L, Specklin S, Kereselidze D, Bouleau A, Dubois S, Quelquejay H, Maillère B, Tournier N, Nozach H, Truillet C. J Nucl Med. 2025 Feb 20:jnumed.124.268586. doi: 10.2967/jnumed.124.268586. • MQ232, A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases", G.Stanajic-Petrovic, M.Keck, P.Barbe, A.Urman, E.Correia, P.Isnard, J.P.Duong Van Huyen, K.Chmeis, S.Siramakan Diarra, S.Palea, F.Theodoro, A.L.Nguyen, F.Castelli, A.Pruvost, W.Zhao, C.Mendre, B.Mouillac, P.Kessler, C.Llorens-Cortes, D.Servent, H.Nozach, B.Maillère, D.Guo*, C.Truillet*, N.Gilles*, J Am Soc Nephrol, 2025 Feb 1;36(2):181-192., doi: 10.1681/ASN.0000000505

• Successful repositioning of mertansine for improved chemotherapy by combining a polymer prodrug approach and PET imaging., Martin-Aubert S, Avrillon K, Tournier N, Bordat A, Tran VL, Ibrahim N, Kereselidze D, Jego B, Potiron L, Tsapis N, Nicolas J, Boissenot T, Truillet C., J Control Release. 2024 Dec 30;378:803-813. doi: 10.1016/j.jconrel.2024.12.050 • “Low-boiling-point perfluorocarbon nanodroplets for adaptable ultrasound-induced blood-brain barrier opening”, Dauba A, Spitzlei C, Bautista KJB, Jourdain L, Selingue E, VanTreeck KE, Mattern JA, Denis C, Ouldali M, Arteni AA, Truillet C, Larrat B, Tsuruta J, Durham PG, Papadopoulou V, Dayton PA, Tsapis N, Novell A., J Control Release. 2024 Oct 22;376:441-456 • “A Cancer Immunoprofiling Strategy Using Mass Spectrometry Coupled with Bioorthogonal Cleavage”, Riberaud, E. Porret, A. PRUVOST, F. Theodoro, A. Nguyen, S. Specklin, D. kereselidze, C. Denis, B. Jego, P. Barbe, M. Keck, T. D'Anfray, B. Kuhnast, D. Audisio C. Truillet* and M. Taran*, Chem. Sci., 2024, DOI:10.1039/D4SC04471A. • “Preoperative PET imaging and fluorescence-guided surgery of human glioblastoma using dual-labeled antibody targeting ETA receptors in a preclinical mouse model: A theranostic approach”, Hautiere M, Vivier D, Dorval P, Pineau D, Kereselidze D, Denis C, Herbet A, Costa N, Bernhard C, Goncalves V, Selingue E, Larrat B, Dancer PA, Hugnot JP, Boquet D, Truillet C, Denat F.(co-last Authors), Theranostics 2024; 14(16):6268-6280. doi:10.7150/thno.98163. https://www.thno.org/v14p6268.htm(https://www.thno.org/v14p6268.htm) • "Tumor-targeted perfluorinated micelles as efficient theranostic agents combining positron emission tomography and radiosensitization”, Godel-Pastre S, Porcel E, Pinna G, Vandamme M, Denis C, Leterrier C, Doris E, Truillet C, Gravel E., ACS Appl Mater Interfaces, 2024 May 1;16(17):21557-21570. doi: 10.1021/acsami.4c00910 • “Brain delivery enabled by transient blood-brain barrier disruption induced by regadenoson: a PET imaging study”., Hosten B, Goutal S, Leterrier S, Corvo C, Breuil L, Barret O, Specklin S, Truillet C, Tournier N. Expert Opin Drug Deliv. 2024 Jun 20:1-11. doi: 10.1080/17425247.2024.2369765.

• "AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors", L.Carmès, G.Bort, F.Lux, L.Seban, P.Rocchi, Z.Muradova, A.Hagege, L.Heinrich-Balard, F.Delolme, V.Gueguen-Chaignon, C.Truillet, S.Crowley, E.Bello, T.Doussineau, M.Dougan, O.Tillement, J.Schoenfeld, N.Brown and R.Berbeco, Nanoscale, 2023, DOI: 10.1039/D3NR04777F • "Synthesis and preclinical fluorescence imaging of dually-functionalized antibody conjugates targeting endothelin receptors positive tumors", D.Vivier, M.Hautière, D.Pineau, P.A.Dancer, A.Herbet, J.P.Hugnot, C.Bernhard, V.Goncalves, C.Truillet, D.Boquet, F.Denat, Bioconjugate Chemistry, 2023, 2023, 34, 11, 2144–2153. • "Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice", L. Meyblum. C. Chevaleyre, S. Susini, B.Jego, F.Deschamps, D.Kereselidze, B.Bonnet, A.Marabelle, T.De Baere, V.Lebon, L. Tselikas, C.Truillet, JITC, 2023;11:e007433. doi: 10.1136/jitc-2023-007433. • “Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction.”, C.Chevaleyre, A.Novell, N.Tournier, A.Dauba, S.Dubois, D.Kereselidze, E.Selingue, B.Jego, B.Maillère, B.Larrat, H.Nozach, C.Truillet, THNO, 2023 Oct 16;13(15):5584-5596. doi: 10.7150/thno.87168 • “Fluorine-18 and radiometals labeling of biomolecules via disulfide rebridging”, M.Richard, S.Martin-Aubert, C.Denis, S.Dubois, H.Nozach, C.Truillet, B.Kuhnast, Bioconjugate Chemistry, 2023, 15;34(11):2123-2132., doi: 10.1021/acs.bioconjchem.3c00440. • “Anticancer drug delivery by focused ultrasound-mediated blood-brain/tumor barrier disruption for glioma therapy: From benchside to bedside”, C.Bérard, C.Truillet, B.Larrat, F.Dhermain, MA.Estève, F.Correard, A.Novell, Pharmacol Ther, 2023 Aug 22;108518. doi: 10.1016/j.pharmthera.2023.108518. • “Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function, S.Goutal, A.Novell, S.Leterrier, L.Breuil, E.Selingue, M.Gerstenmayer, S.Marie, B.Saubaméa, F.Caillé, O.Langer, C.Truillet, B.Larrat, N.Tournier, JCR, 2018 Dec 28;292:210-220. doi: 10.1016/j.jconrel.2018.11.009. • “Sonoporation-assisted micelle delivery in subcutaneous glioma-bearing mice evaluated by PET/Fluorescent bi-modal imaging”, E.Porret, S.Hoang, C.Denis, E.Doris, M.Hruby, A. Novell, G.Edmond, C.Truillet, Nanoscale, 2023 Aug 3;15(30):12574-12585. doi: 10.1039/d3nr01539d. • “Design, radiosynthesis and evaluation of new fluorinated analogs of MeDAS for myelin PET imaging", S.Beuché, M.A.Peyronneau, B.Jego, C.Denis, P.Bourbon, C.Chauvière, C.Santerre, C.Truillet, B.Kuhnast, F.Caillé, J Med Chem, 2023, 2023 Jun 22;66(12):8030-8042. doi: 10.1021/acs.jmedchem.3c00325 • “ImmunoPET imaging-based pharmacokinetic profiles of an antibody and its Fab targeting endothelin A receptors on glioblastoma stem cells in a preclinical orthotopic model”, M.Hautiere, D.Vivier, D.Pineau, C.Denis, D.Kereselidze, A.Herbet, N.Costa, V.Goncalves, E.Selingue, B.Larrat, JP.Hugnot , F.Denat, D.Boquet, C.Truillet, EJNMMI, 2023, doi: 10.1007/s00259-023-06268-3. • “Refining the delivery and therapeutic efficacy of cetuximab using focused ultrasound in a mouse model of glioblastoma: an 89Zr-cetuximab immunoPET study.” Porret E, Kereselidze D, Dauba A, Schweitzer-Chaput A, Jegot B, Selingue E, Tournier N, Larrat B, Novell A, Truillet C, Eur J Pharm Biopharm, 2023 Jan;182:141-151. doi: 10.1016/j.ejpb.2022.12.006.

• “Refining the delivery and therapeutic efficacy of cetuximab using focused ultrasound in a mouse model of glioblastoma: an 89Zr-cetuximab immunoPET study.” Porret E, Kereselidze D, Dauba A, Schweitzer-Chaput A, Jegot B, Selingue E, Tournier N, Larrat B, Novell A, Truillet C*, Eur J Pharm Biopharm. 2022 Dec 15:S0939-6411(22)00300-9. doi: 10.1016/j.ejpb.2022.12.006. • “Impact of cytochrome induction or inhibition on the plasma and brain kinetics of [11C]metoclopramide, a PET probe for P-glycoprotein function at the blood-brain barrier”, L.Breuil, N.Ziani, S.Leterrier, G.Hugon, F.Caillé, V.Bouilleret, C.Truillet, M.Goislard, M.El Biali, M. Bauer, O.Langer, S.Goutal, N.Tournier, pharmaceutics, 2022, 2058870. • “TSPO PET Imaging as a Potent Non-Invasive Biomarker for Diffuse Intrinsic Pontine Glioma in a Patient-Derived Orthotopic Rat Model”, C.Chevaleyre, D.Kereselidze, F. Caillé, N.Tournier, N.G.Olaciregui, A.Winkeler, X. Declèves B.Jego, S.Cisternino, S.Auvity, CTruillet*, Int. J. Mol. Sci. 2022, 23, 12476. • “Pharmacokinetics derived from PET imaging of inspiring radio-enhancer platinum nanoparticles”, XYang, VL Tran, H.Remita, F.Savina, C.Denis, D.Kereselidze, B.Jego, S.Lacombe, E.Porcel* & C.Truillet*, Nanomedicine: Biology, and Medicine, Volume 46, 2022, 102603. • “Impact of Radiolabeling Strategies on the Pharmacokinetics and Distribution of an Anti-PD-L1 PET Ligand”, V.L.Tran, A.Bouleau, H.Nozach, M.Richard, C.Chevaleyre, S.Dubois, D.Kereselidze, B.Kuhnast, M.J. Evans, S.Specklin*, and C.Truillet*, Mol. Pharmaceutics 2022, https://doi.org/10.1021/acs.molpharmaceut.2c00497 • “Pharmacokinetic Imaging Using 99mTc-Mebrofenin to Untangle the Pattern of Hepatocyte Transporter Disruptions Induced by Endotoxemia in Rats.”, Marie S, Hernández-Lozano I, Le Vée M, Breuil L, Saba W, Goislard M, Goutal S, Truillet C, Langer O, Fardel O, Tournier N., Pharmaceuticals (Basel). 2022 Mar 24;15(4):392. doi: 10.3390/ph15040392.

• "Optimizing immunoPET imaging of tumor PD-L1 expression: pharmacokinetics, biodistribution and dosimetric comparisons of 89Zr-labeled anti-PD-L1 antibody formats", A.Bouleau, H.Nozach, S.Dubois, D.Kereselidze, C.Chevaleyre, C.I. Wang, M.J. Evans, V.Lebon, B.Maillère, C.Truillet, JNM, 2021, jnumed.121.262967. • "Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?", L Breuil, S Marie, S Goutal, S Auvity, C Truillet, W Saba, O Langer, F.Caillé, N.Tournier, JCBFM, 2021, 0271678X211045444. • "Imaging-based characterization of a Slco2b1(-/-) mouse model using [11C]erlotinib and [99mTc]mebrofenin as probe substrates", S.Marie, I.Hernández-Lozano, L.Breuil, C.Truillet, S.Hu, A.Sparreboom, N.Tournier, O.Langer, pharmaceutics, Pharmaceutics, 2021 Jun 21;13(6):918. • "Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [ 11 C]erlotinib", N.Tournier, S.Goutal, S.Mairinger, I.Hernández-Lozano, T.Filip, M.Sauberer, F.Caillé, L.Breuil, J.Stanek, A.F Freeman, G.Novarino, C.Truillet, T.Wanek, O.Langer J Cereb Blood Flow Metab, 2021 Jul;41(7):1634-1646. • "Quantitative tissue pharmacokinetics and EPR effect of AGuIX® nanoparticles: a multimodal imaging study in an orthotopic glioblastoma rat model and healthy macaque", VL Tran, F Lux, N.Tournier, B.Jego, X. Maître, M.Anisorac,C.Comtat,S.Jan, K.Selmeczi, M.J. Evans, O.Tillement, B. Kuhnast, C.Truillet, Adv Healthc Mater, 2021 Aug;10(16):e2100656.

• "PET imaging of immune checkpoint proteins in oncology”, A.Bouleau, V.Lebon, C.Truillet, Pharmacology & Therapeutics, 107786, ISSN 0163-7258, https://doi.org/10.1016/j.pharmthera.2020.107786.(https://doi.org/10.1016/j.pharmthera.2020.107786) • “An analysis of Isoclonal Antibody formats suggests a role of measuring PD-L1 with low molecular weight PET radiotracers”, J. Wei, YH Wang, CY Lee, C. Truillet, D.Y. Oh, Y. Xu, D. Ruggero, R.R. Flavell, H.F. VanBrocklin, Y. Seo, C.S. Craik, L. Fong, C. Wang, MJ. Evans, Mol Imaging Biol, 2020, 22(6):1553-1561. • “Impact of blood-brain barrier permeabilization induced by ultrasound associated to microbubbles on the brain delivery and kinetics of cetuximab: an immunoPET study using 89Zr-cetuximab”, VL Tran, A.Novell, N. Tournier, M.Gerstenmayer, A.Schweitzer-Chaput, C.Mateos, B.Jego, A.Bouleau, H.Nozach, A.Winkeler, B.Kuhnast, B.Larrat, C.Truillet*, Just accepted, JCR (* corresponding author) • “A snake toxin as a theranostic agent for the type 2 vasopressin receptor”, L.Droctové, M. Lancien, VL. Tran, M.Susset, B.Jego, F.Theodoro, P.Kessler, G.Mourier, P. Robin, S. Palea, S.Siramakan Diarra, A.Flahault, C. Llorens-Cortes, A.Chorfa, M.Corbani, B.Mouillac, C.Mendre, A.Pruvost, D.Servent, C.Truillet, N.Gilles, Theranostics 2020; doi:10.7150/thno.47485; accepted • - “Validation of Pharmacological Protocols for Targeted Inhibition of Canalicular MRP2 Activity in Hepatocytes Using [ 99m Tc]mebrofenin Imaging in Rats”, S.Marie, I.Hernández-Lozano, L.Breuil, W.Saba, A.Novell, JL.Gennisson, O.Langer, C.Truillet, N.Tournier, Pharmaceutics, 2020 May 27;12(6):E486 • “A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography.”, Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Blecha JE, VanBrocklin HF, Seo Y, Sayeed M, Feldman BJ, Aggarwal R, Behr SC, Shao H, Wilson DM, Villanueva-Meyer JE, Gestwicki JE, Evans MJ, ACS Chem Biol. 2020 Apr 15. doi: 10.1021/acschembio.9b01043. • “Longitudinal mouse-PET imaging: a reliable method for estimating binding parameters without a reference region or blood sampling", C.Wimberley, D.Nguyen, C.Truillet, M.Peyronneau, Z. Gulhan, M.Tonietto, F.Boumezbeur, R.Boisgard, S.Chalon, V.Bouilleret, I.Buvat, EJNM, 2020, doi: 10.1007/s00259-020-04755-5

• "Profiling the surfaceome identifies therapeutic targets for cells with hyperactive mTORC1 signaling”, J.Wei, K.Leung, C.Truillet, D. Ruggero, J.Wells M.J. Evans, Molecular & Cellular Proteomics December 2, 2019, mcp.RA119.001785 • "New fluorine-18 pretargeting PET imaging by bioorthogonal chlorosydnone-cycloalkyne click reaction », M.Richard, C.Truillet, VL.Tran, H.Liu, K.Porte, D.Audisio, M.Roche, B.Jego, S.Cholet, F.Fenaille, B.Kuhnast, F.Taran, S.Specklin, Chem Commun (Camb). 2019 Aug 27;55(70):10400-10403 • “TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma”, H.Pigeon, E.A Pérès, C.Truillet, B.Jego, F.Boumezbeur, F.Caillé, B.Zinnhardt, A.H Jacobs, D.Le Bihan, A.Winkeler, Neuro-Oncology, 2019, noz029.

• “A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4”, A.Moroz, C.Lee,Y.Wang, J.C.Hsiao, N.Sevillano, C.Truillet, C.S.Craik, L.Fong, C.Wnag, M.J.Evans, Bioconjugate Chem., 2018, 29 (10), pp 3476–3482. • “AGuIX® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine”, F.Lux, V.L.Tran, E.Thomas, S.Dufort, F.Rossetti, M.Martini, C.Truillet, T.Doussineau, G.Bort, F.Denat, F.Boschetti, G.Angelovski, A.Detappe, Y.Crémillieux, N.Mignet, B.Th.Doan, B.Larrat, S.Meriaux, E.Barbier, S.Roux, P.Fries, A.Müller, M.C.Abadjian, C.Anderson, E.Canet-Soulas, P.Bouziotis, M.Barberi-Heyob, C.Frochot, C.Verry, J.Balosso, M.Evans, J.Sidi-Boumedine, M.Janier, K.Butterworth, S.McMahon, K.Prise, M.T.Aloy, D.Ardail, C.Rodriguez-Lafrasse, E.Porcel, S.Lacombe, R.Berbeco, A.Allouch, J.L.Perfettini, C.Chargari, E.Deutsch, G.Le Duc, O.Tillement, Br J Radiol 2018; 91: 20180365. • “Measuring glucocorticoid receptor expression in vivo with PET”, C.Truillet, MF.L. Parker, LT. Huynh, J.Wei, K.M. Jami, Y.Wang, Y.S.Shen, R.Sriram, D.M. Wilson, J.Kurhanewicz, M.J. Evans, Oncotarget. 2018; 9:20399-20408 • “Longitudinal imaging of glial cell activation with TSPO PET in a mouse model of mesial temporal lobe epilepsy towards identification of optimal treatment windows”, DL.Nguyen, C.Wimberley, C.Truillet*, B.Jego, F.Caillé, G.Pottier, R.Boisgard, I.Buvat, V.Bouilleret, Epilepsia. 2018 Jun;59(6):1234-1244. doi: 10.1111/epi.14083, * corresponding author. • “Development of a stress response therapy targeting aggressive prostate cancer”, H.G Nguyen, C.S.Conn, Y.Kye, L.Xue, C.MForester, J.E.Cowan, A.C.Hsieh, J.T.Cunningham, C.Truillet, J.Simko, F.Tameire, M.J.Evans, C.P.Evans, J.C.Yang, B.Hann, C.Koumenis, P.Walter, P.R.Carroll, D.Ruggero, Sci Transl Med. 2018 May 2;10(439). • “Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins”, A.J.Martinko, C.Truillet, O.Julien, J.E Diaz, M.A.Horlbeck, G.Whiteley, J.Blonder, J.S.Weissman, S.Bandyopadhyay,M.J.Evans, and J.A. Wells, eLife. 2018; 7: e31098.

• “Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade”, H.Lue, J. Podolak, K. Kolahi, L. Cheng, S. Rao, D. Garg, C. Xue, J. K. Rantala, J. W. Tyner, K. L. Thornburg, A. Martinez-Acevedo, J. Liu, C. L. Amling, C. Truillet, S. M. Louie, K. E. Anderson, M. J. Evans, V. B. O'Donnell, D. K. Nomura, J. M. Drake, A. Ritz, and G. V. Thomas, Genes Dev. 2017 Oct 15;31(20):2067-2084 • “Imaging PD-L1 expression with immunoPET”, C.Truillet, H.L. J. Oh, S.P. Yeo, C.Y. Lee, L.T. Huynh, J. Wei, M.F. L. Parker, C.M. Blakely, N. Sevillano, Yu. Wang, Y.S. Shen, V. Olivas, K. Jami, A. Moroz, B. Jego, E. Jaumain, L. Fong, C.S. Craik, A.J. Chang, T.G. Bivona, C. Wang, and M.J. Evans, Bioconjugate Chem., 2018, 29 (1), pp 96–103 • “Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen”, F. Jesus Cortez, P. Nguyen, C. Truillet, B. Tian, K.M. Kuchenbecker, M.J. Evans, P. Webb, M.P. Jacobson, R.J. Fletterick, P.M. England, ACS Chem Biol. 2017 Nov 2. doi: 10.1021/acschembio.7b00702. • “Real time transferrin-based PET detects MYC-positive prostate cancer”, R. Aggarwal, S. Behr, P. L Paris, C. Truillet, M. F.L. Parker, L. T. Huynh, J. Wei, B. Hann, J. Youngren, G. Premasekharan, J. Huang, N. Ranatunga, E. Chang, K. T. Gao, C. J Ryan, E. J. Small and M. J Evans, Mol Cancer Res. 2017 Sep;15(9):1221-1229 • “Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin”. C. Truillet, J.T. Cunningham, M.F.L. Parker, L.T. Huynh, C.S. Conn, D.Ruggero, J.S. Lewis, M.J Evans, Clin Cancer Res. 2017 Jun 15;23(12):3045-3052. • “68Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy”, P. Bouziotis, D. Stellas, E. Thomas, C. Truillet, C. Tsoukalas, F. Lux, T. Tsotakos, S. Xanthopoulos, M. Paravatou-Petsotas, A. Gaitanis, L. A. Moulopoulos, V. Koutoulidis, C. D Anagnostopoulos, O. Tillement, Nanomedicine (Lond). 2017 Jul;12(13):1561-1574 • “Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience” T.A. Hope* C.Truillet*, E.C.Ehman, A.A.Omoreih, R.Aggarwal, C.JRyan, P.R.Carroll, E.J.Small, M.J.Evans, J Nucl Med. 2017 Jan;58(1):81-84, *Co-First

• “Synthesis and characterization of 89Zr-labeled ultrasmall nanoparticles”, C.Truillet, E.Thomas, F.Lux, L.T. Huynh, O.Tillement, and M.J. Evans, Mol. Pharmaceutics, 2016, 13 (7), pp 2596–2601. • “A reactivity-based [18F]FDG probe for in vivo formaldehyde imaging using positron emission tomography”, W.Liu, C.Truillet, R.Flavell, T.F.Brewer, M.J.Evans, D.M.Wilson, C.J.Chang, Chem.Sci., 2016, 7, pp 5503-5507. • “Applying 89Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins”, M.G.Doran, K.E.Carnazza, J.M.Steckler, D.E.Spratt, C.Truillet, J.Wongvipat, C.L.Sawyers, J.S. Lewis, M.J.Evans, Mol. Pharmaceutics January 2016, 2016, 13 (2), pp 683–688. • “Site-Specific Radiofluorination of Peptides with 8-[18F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase”, C.Drake, N.Sevillano, C.Truillet, C.Craik, H.VanBrocklin, M.Evans, ACS Chem. Biol., March 2016, 11 (6), pp 1587–1594. • “[1-11C]Ascorbic and [1-11C]Dehydroascorbic Acid, An Endogenous Redox Pair for Sensing Reactive Oxygen Species Using Positron Emission Tomography”, V.Carroll, C.Truillet, B.Shen, R.R.Flavell, X.Shao, M.Evans, H.VanBrocklin, P.J.H.Scott, F.Chin, D.M.Wilson, Chem. Commun., March 2016, 52, pp 4888-4890. • “Caged [18F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography”, R.Flavell, C.Truillet, M.K.Regan, T.Ganguly, J.E.Blecha, J.Kurhanewicz, H.F.VanBrocklin, K.R.Keshari, C.J.Chang, M.J.Evans, D.M.Wilson, 2016, Bioconjugate Chem., 27 (1), pp 170–178

• “Long-Term in Vivo Clearance of Gadolinium-Based AGuIX Nanoparticles and Their Biocompatibility after Systemic Injection”, L.Sancey, S.Kotb, C.Truillet, F.Appaix, A.Marais, E.Thomas, B.VanDerSanden, J.P.Klein, B.Laurent, M.Cottier, R.Antoine, P.Dugourd, G.Panczer, F.Lux, P.Perriat, V.Motto-Ros, O.Tillement, ACS nano, 2015, 9(3), pp 2477-248829. “Ultrasmall particles for Gd-MRI and 68Ga-PET dual imaging”, C.Truillet, P.Bouziotis, C.Tsoukalas, J.Brugière, M.Martini, L.Sancey, T.Brichart, F.Denat, F.Boschetti, U.Darbost, I.Bonnamour, D.Stellas, C.D. Anagnostopoulos, V.Koutoulidis, L. A.Moulopoulos, P.Perriat, F.Lux and O.Tillement, Contrast Media Mol. Imaging, 2015, 10, pp 309 – 319.

• “Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment” G.Le Duc, S.Roux, A.Paruta-Tuarez, S.Dufort, E.Brauer, A.Marais, C.Truillet, L.Sancey, P.Perriat, F.Lux and O.Tillement, Cancer Nanotechnology, 2014, 5, 4. • “Nanosondes hybrides multimodales”, C.Truillet, F.Lux, S.Roux, P.Perriat, O.Tillement, Les Techniques de l'Ingénieur, 2014, Article / Réf : NM4020 v1.

“A Top-Down Synthesis Route to Ultrasmall Multifunctional Gd-Based Silica Nanoparticles for Theranostic Applications”, A.Mignot, C.Truillet, et al., Chem. Eur. J., 2013, 19, 19, pp 6122-36. “Coupling of HPLC with ESI-MS for Studying the Aging of Ultrasmall Multifunctional Gd-based Silica Nanoparticles”, C. Truillet, F. Lux, O. Tillement, P. Dugourd, R. Antoine, Anal. Chem., 2013, 85, 21, pp 10440–10447. “In vivo evidence of the targeting of cartilaginous tissue by pyridinium functionalized nanoparticles”, J.Morlieras, JM. Chezal, E.Miot-Noirault, A.Vidal, S.Besse, D.Kryza, C.Truillet, A.Mignot, R.Antoine, P.Dugourd, F.Redini, L.Sancey, F.Lux, P.Perriat, M.Janier, O.Tillement, Chemical Communications, 2013, 49, pp 3046-3048. “Development of gadolinium based nanoparticles having an affinity towards melanin” J.Morlieras, JM.Chezal, E.Miot-Noirault, A.Roux, L.Heinrich-Balard, R.Cohen, S.Tarrit, C.Truillet, A.Mignot, R.Hachani, D.Kryza, R.Antoine, P.Dugourd, P.Perriat, M.Janier, L.Sancey, F.Lux, O.Tillement, Nanoscale, 2013, 5, 4, pp 1603-15. “Functionalization of Small Rigid Platforms with Cyclic RGD Peptides for Targeting Tumors Overexpressing alphavbeta3-Integrins.”, J.Morlieras, S. Dufort, L. Sancey, C. Truillet, A. Mignot, F. Rossetti, M. Dentamaro, S. Laurent, L. Vander Elst, R.N. Muller, R. Antoine, P. Dugourd, S. Roux, P. Perriat, F. Lux, J.L. Coll, O. Tillement, Bioconjugate chemistry, 2013, 24, 9, pp 1584–159. “Bifunctional polypyridyl-Ru(II) complex grafted onto gadolinium-based nanoparticles for MR-imaging and photodynamic therapy”, C. Truillet, F. Lux,J. Moreau, M. Four, L. Sancey, S. Chevreux, G. Roullin, G. Boeuf, P.Perriat, C. Frochot, R. Antoine, P. Dugourd, C. Portefaix, C. Hoeffel, M. Barberi-Heyob, C. Terryn, L. van Gulick, S. Dukic, G. Lemercier and O. Tillement, Dalton Trans., 2013, 42, 34, pp 12410-20. “X-Ray-Induced Singlet Oxygen Activation with Nanoscintillator-Coupled Porphyrins”, C. Truillet, A.L. Buli,, R. Chouikrat, F. Lux, C. Frochot, D. Amans, G. Ledoux, O. Tillement, P. Perriat, M. Barberi-Heyob, C. Dujardin, J. Phys. Chem. C., 2013, 117, 41, pp 21583–21589. “Energy transfer from pyridine molecules towards europium cations contained in sub 5-nm” C. Truillet, F. Lux, T. Brichart, G.W. Lu, Q.H. Gong, P. Perriat, M. Martini, O. Tillement, J. Appl. Phys., 2013, 114, pp 114308-1/114308-10.

• R. Antoine, C. Truillet, P. Dugourd, F. Lux, O. Tillement, « Procédé de caractérisation de particules », 2013, FR13 58740 • M. Evans, M. Parker, C. Truillet, Innovation Ventures, « Novel Radiotracers for Imaging Glucocorticoid Receptor in Treatment-resistant Cancer Patients », Tech ID: 27425 / UC Case 2016-096-0 • E.Doris, E.Gravel, S.Godel, C.Truillet, E.Porcel, and L.Jamgotchian, “Perfluorinated micelles and medical uses thereof.”, BD22719 • Frédéric Taran, Charles Truillet, Olivier Provost, Maxime Riberaud, Multiplex cancer cell profiling using MS-tagged probes containing an iminosydnone cleavable linker, EP24305986, 2024